Literature DB >> 22882958

Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients.

Ana V Villar1, Raquel García, David Merino, Miguel Llano, Manuel Cobo, Cecilia Montalvo, Rafael Martín-Durán, María A Hurlé, J Francisco Nistal.   

Abstract

BACKGROUND: Various human cardiovascular pathophysiological conditions associate aberrant expression of microRNAs (miRNAs) and circulating miRNAs are emerging as promising biomarkers. In mice, myocardial miR-21 overexpression is related to cardiac fibrosis elicited by pressure overload. This study was designed to determine the role of myocardial and plasmatic miR-21 in the maladaptive remodeling of the extracellular matrix induced by pressure overload in aortic stenosis (AS) patients and the clinical value of miR-21 as a biomarker for pathological myocardial fibrosis.
METHODS: In left ventricular biopsies from 75 AS patients and 32 surgical controls, we quantified the myocardial transcript levels of miR-21, miR-21-targets and ECM- and TGF-β-signaling-related elements. miR-21 plasma levels were determined in 25 healthy volunteers and in AS patients. In situ hybridization of miR-21 was performed in myocardial sections.
RESULTS: The myocardial and plasma levels of miR-21 were significantly higher in the AS patients compared with the controls and correlated directly with the echocardiographic mean transvalvular gradients. miR-21 overexpression was confined to interstitial cells and absent in cardiomyocytes. Using bootstrap validated multiple linear regression, the variance in myocardial collagen expression was predicted by myocardial miR-21 (70% of collagen variance) or plasma miR-21 (52% of collagen variance), together with the miR-21 targets RECK and PDCD4, and effectors of TGF-ß signaling.
CONCLUSIONS: Our results support the role of miR-21 as a regulator of the fibrotic process that occurs in response to pressure overload in AS patients and underscore the value of circulating miR-21 as a biomarker for myocardial fibrosis.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  AS; Aortic stenosis; Col; ECM; FN; LV; MicroRNA; Myocardial fibrosis; PDCD4; PTEN; Plasma miR-21; RECK; SPRY1; TAK-1; TGF-ß signaling; TGF-β; TGF-β activated kinase-1; TIMP3; aortic stenosis; collagen; extracellular matrix; fibronectin 1; left ventricle; miRNA; microRNA; phosphatase and tensin homolog; programmed cell death 4; reversion-inducing-cysteine-rich protein with kazal motifs; sprouty homolog 1; tissue inhibitor of metalloproteinase 3; transforming growth factor-β

Mesh:

Substances:

Year:  2012        PMID: 22882958     DOI: 10.1016/j.ijcard.2012.07.021

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  54 in total

Review 1.  Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.

Authors:  Christian Schulte; Dirk Westermann; Stefan Blankenberg; Tanja Zeller
Journal:  World J Cardiol       Date:  2015-12-26

Review 2.  MicroRNAs as modulators of longevity and the aging process.

Authors:  Holly E Kinser; Zachary Pincus
Journal:  Hum Genet       Date:  2019-07-11       Impact factor: 4.132

Review 3.  The therapeutic potential of miRNAs in cardiac fibrosis: where do we stand?

Authors:  Wino J Wijnen; Yigal M Pinto; Esther E Creemers
Journal:  J Cardiovasc Transl Res       Date:  2013-07-03       Impact factor: 4.132

4.  MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children.

Authors:  Ma C Sánchez-Gómez; K A García-Mejía; M Pérez-Díaz Conti; G Díaz-Rosas; I Palma-Lara; R Sánchez-Urbina; M Klünder-Klünder; J A Botello-Flores; N A Balderrábano-Saucedo; A Contreras-Ramos
Journal:  Pediatr Cardiol       Date:  2017-04-05       Impact factor: 1.655

Review 5.  In vitro 3D model and miRNA drug delivery to target calcific aortic valve disease.

Authors:  Casper F T van der Ven; Pin-Jou Wu; Mark W Tibbitt; Alain van Mil; Joost P G Sluijter; Robert Langer; Elena Aikawa
Journal:  Clin Sci (Lond)       Date:  2017-02-01       Impact factor: 6.124

Review 6.  Calcific Aortic Valve Disease: Part 2-Morphomechanical Abnormalities, Gene Reexpression, and Gender Effects on Ventricular Hypertrophy and Its Reversibility.

Authors:  Ares Pasipoularides
Journal:  J Cardiovasc Transl Res       Date:  2016-05-16       Impact factor: 4.132

7.  Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase.

Authors:  Jing Wu; Salim R Thabet; Annet Kirabo; Daniel W Trott; Mohamed A Saleh; Liang Xiao; Meena S Madhur; Wei Chen; David G Harrison
Journal:  Circ Res       Date:  2013-12-17       Impact factor: 17.367

Review 8.  Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease.

Authors:  Albert Busch; Suzanne M Eken; Lars Maegdefessel
Journal:  Ann Transl Med       Date:  2016-06

Review 9.  Noncoding RNAs and myocardial fibrosis.

Authors:  Thomas Thum
Journal:  Nat Rev Cardiol       Date:  2014-09-09       Impact factor: 32.419

Review 10.  Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers.

Authors:  Perry V Halushka; Andrew J Goodwin; Marc K Halushka
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.